Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts.

Cobb MS, Tao S, Shortt K, Girgis M, Hauptman J, Schriewer J, Chin Z, Dorfman E, Campbell K, Heruth DP, Shohet RV, Dawn B, Konorev EA. Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts. Am J Physiol Heart Circ Physiol. 2022 12 01; 323(6):H1091-H1107.

View in: PubMed

subject areas

Animals
Cardiomyopathies
Doxorubicin
Endothelial Cells
Mice
Mice, Knockout
Quality of Life
Smad3 Protein
Transforming Growth Factor beta

authors with profiles

Ralph V. Shohet, MD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support